Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up – Still a Buy?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped up prior to trading on Friday . The stock had previously closed at $25.61, but opened at $26.42. Dyne Therapeutics shares last traded at $25.71, with a volume of 40,896 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DYN. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday. Chardan Capital reiterated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Piper Sandler restated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.42.

Dyne Therapeutics Stock Up 0.5 %

The stock has a market cap of $2.62 billion, a PE ratio of -7.23 and a beta of 1.09. The company has a fifty day moving average price of $30.39 and a 200 day moving average price of $35.23.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 782 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the sale, the director now directly owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now directly owns 131,636 shares in the company, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 180,046 shares of company stock worth $6,300,265 over the last ninety days. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Dyne Therapeutics during the second quarter valued at $217,000. Nisa Investment Advisors LLC boosted its holdings in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Dyne Therapeutics by 52.5% in the second quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company’s stock worth $10,993,000 after acquiring an additional 107,233 shares during the period. Legato Capital Management LLC raised its holdings in shares of Dyne Therapeutics by 35.3% during the second quarter. Legato Capital Management LLC now owns 15,480 shares of the company’s stock valued at $546,000 after purchasing an additional 4,035 shares during the last quarter. Finally, Lisanti Capital Growth LLC raised its holdings in shares of Dyne Therapeutics by 22.5% during the second quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company’s stock valued at $3,746,000 after purchasing an additional 19,530 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.